CXJ2080
CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC50 of 0.88 nM. CXJ2080 recruits VHL E3 ligase to induce ubiquitin-proteasome-dependent CDK7 degradation, disrupts the CDK7-cyclin H-MAT1 complex, suppresses CDK7-dependent phosphorylation of RNA polymerase II CTD Ser5, CDK1 Thr161, and CDK2 Thr160. CXJ2080 activates the p53-p21 axis, suppresses MYC-driven signaling, induces leukemia cell cycle arrest, apoptosis, and differentiation, reduces CD117 expression, spares platelets and normal PBMCs, maintains sustained CDK7 degradation post-washout. CXJ2080 can be used for the research of acute leukemia.
(Pink: CDK7 ligand (HY-183071); Blue: VHL ligand (HY-170348); Black: linker).
For research use only. We do not sell to patients.
- Formula: C51H68ClN11O6S2
- Molecular Weight:1030.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK7 |
In Vitro
CXJ2080 (0.5-200 nM; 6 h) potently degrades CDK7 in MV4-11 acute myeloid leukemia cells with a DC50 of 0.88 nM and >98% maximum degradation efficiency[1].
CXJ2080 (72 h) potently inhibits the proliferation of RS4;11 acute lymphoblastic leukemia cells (IC50 = 17.29 nM) and MV4-11 acute myeloid leukemia cells (IC50 = 4.31 nM)[1].
CXJ2080 (72 h) inhibits the proliferation of primary acute myeloid leukemia patient-derived cell samples[1].
CXJ2080 (100 nM; 4 h pretreatment) induces sustained CDK7 degradation in MV4-11 acute myeloid leukemia cells, with suppression maintained for 48 h post-washout[1].
CXJ2080 (5-100 nM; 8 h) induces dose-dependent CDK7 degradation, p53 accumulation, Myc downregulation, and a biphasic p21 protein response in MV4-11 acute myeloid leukemia cells[1].
CXJ2080 (5-100 nM; 12 h) induces dose-dependent cell cycle arrest in MV4-11 acute myeloid leukemia cells, with increased SubG1 phase accumulation at higher concentrations[1].
CXJ2080 (5-100 nM; 48 h) induces dose-dependent apoptosis in MV4-11 acute myeloid leukemia cells[1].
CXJ2080 (5-100 nM; 24 h) significantly reduces CD117 (c-KIT) stemness marker expression in MV4-11 acute myeloid leukemia cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4-11 acute myeloid leukemia cells
-
Concentration:100 nM
-
Incubation Time:4 h
-
Result:Maintained CDK7 degradation for 48 h post-washout.
-
Cell Line:MV4-11 acute myeloid leukemia cells
-
Concentration:5 nM; 20 nM; 100 nM
-
Incubation Time:8 h
-
Result:Degraded CDK7 in a dose-dependent manner.
Induced accumulation of p53 protein.
Downregulated Myc protein.
Caused a biphasic response in p21 protein levels (upregulated at low concentrations, downregulated at high concentrations).
-
Cell Line:MV4-11 acute myeloid leukemia cells
-
Concentration:5 nM; 20 nM; 100 nM
-
Incubation Time:12 h
-
Result:Induced cell cycle arrest in a dose-dependent manner.
Increased accumulation of cells in the SubG1 phase at higher concentrations.
-
Cell Line:MV4-11 acute myeloid leukemia cells
-
Concentration:5 nM; 20 nM; 100 nM
-
Incubation Time:48 h
-
Result:Induced apoptosis in a dose-dependent manner.
Showed a higher proportion of apoptotic cells observed at higher concentrations.
Exhibited more potent apoptotic effects than TZ1104.
Parmacokinetics
In Vivo
CXJ2080 (20-50 mg/kg; i.v.; every other day; 3 weeks) administered at 50 mg/kg every other day via intravenous injection achieves potent tumor growth inhibition with selective CDK7 degradation in MV4-11 xenograft tumors, while sparing PBMCs and maintaining normal platelet parameters[1].
CXJ2080 (20 mg/kg; i.v.; every other day; 21 days) administered at 20 mg/kg every other day via intravenous injection significantly improves survival in mice with disseminated Molm13 acute myeloid leukemia[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nu/Nu (female; 6-8 weeks old; implanted subcutaneously in
the right flank with 5 × 106 RS4;11 cells for a RS4;11 subcutaneous xenograft model)[1] -
Dosage:20 mg/kg; 50 mg/kg
-
Administration:i.v.; every other day; 2 weeks
-
Result:Resulted in tumor weights similar to vehicle controls at 20 mg/kg.
Significantly reduced tumor weights relative to vehicle controls at 50 mg/kg.
Achieved robust CDK7 degradation in tumor tissues at 50 mg/kg.
Caused no significant reduction in CDK7 levels in PBMCs at 50 mg/kg.
-
Animal Model:Nu/Nu (female; 6-8 weeks old; implanted subcutaneously in
the right flank with 5 × 106 MV4-11cells for a MV4-11 subcutaneous xenograft model)[1] -
Dosage:20 mg/kg; 50 mg/kg
-
Administration:i.v.; every other day; 3 weeks
-
Result:Resulted in tumor weights similar to vehicle controls at 20 mg/kg.
Significantly reduced tumor weights relative to vehicle controls at 50 mg/kg.
Achieved robust CDK7 degradation in tumor tissues at 50 mg/kg.
Caused no significant reduction in CDK7 levels in PBMCs at 50 mg/kg.
Maintained stable platelet counts, platelet-large cell ratio (P-LCR), and plateletcrit (PCT) throughout the treatment period at 50 mg/kg.
-
Animal Model:NOD scid gamma (NSG) (female; 6-8 weeks old; inoculated intravenously with 2 × 104
Molm13 cells via the tail vein for a Molm13 disseminated xenograft model)[1] -
Dosage:20 mg/kg
-
Administration:i.v.; every other day; 21 days
-
Result:Significantly extended the survival of Molm13 tumor-bearing mice relative to vehicle controls.
Maintained a low leukemia burden in spleens of two surviving mice at the experimental endpoint.
Chemical Information
-
Molecular Weight 1030.74
-
Formula C51H68ClN11O6S2
-
SMILES
O=C([C@H]1N(C([C@@H](N2N=NC(CCCCCCC(N[C@H]3CC[C@H](NC4=NC=C(Cl)C(NC5=CC=CC=C5S(=O)(C(C)C)=O)=N4)CC3)=O)=C2)C(C)(C)C)=O)C[C@H](O)C1)N[C@H](C6=CC=C(C7=C(C)N=CS7)C=C6)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)